Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

<p>Abstract</p> <p>Background</p> <p>Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is considered to have a favorable safety profile, adverse ev...

Full description

Bibliographic Details
Main Authors: Colin Guillaume, Copin Marie, Scherpereel Arnaud, Makris Demosthenes, Brun Luc, Lafitte Jean, Marquette Charles
Format: Article
Language:English
Published: BMC 2007-08-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/7/150

Similar Items

Similar Items